解读所有菌性谷氨酸酶1抑制剂作为抗癌剂的风景
Chiara Vagaggini1, Pasqualina D'Ursi2, Federica Poggialini1
1Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Bioorganic chemistry
|May 1, 2025
概括
谷氨酸酶1 (GLS1) 抑制剂对于癌症治疗至关重要. 本综述详细介绍了可逆和不可逆GLS1抑制剂的最新进展,指导未来的药物设计,用于增强抗癌治疗.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 谷氨酸是癌细胞增殖的关键能量来源.
- 谷氨酶1 (GLS1) 是谷氨溶解中的速度限制酶,使其成为一个有前途的治疗标.
- 目前的GLS1抑制剂,如CB-839和IPN60090,临床进展有限,需要进一步研究.
研究的目的:
- 审查过去六年中可逆性全性GLS1抑制剂的发现和发展.
- 分析这些抑制剂的结构相似性和差异,包括BPTES和CB-839类似物.
- 提供针对GLS1.1的新型不可逆转的全抑制剂的概述.
主要方法:
- 在过去六年内披露的GLS1抑制剂的文献综述.
- 基于与已知的化合物结构相似性的抑制剂的分类 (BPTES,CB-839).
- 对影响GLS1抑制的结合相互作用和结构特征的分析.
主要成果:
- 详细描述可逆性全性GLS1抑制剂,包括宏环,亚醇和其他衍生物.
- 引入一类新的不可逆转的全抑制剂,针对GLS1.1.的Lys320残留物.
- 关于CB-839和IPN60090.0.的关键生物学研究的摘要
结论:
- 新型GLS1抑制剂的开发,无论是可逆的还是不可逆的,对改善抗癌疗法具有显著的前景.
- 了解结合相互作用对于设计更有效的GLS1抑制剂至关重要.
- 对GLS1向治疗的进一步研究可以扩大癌症治疗的选择.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Allosteric Regulation
57.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


